Dr. Sam Sternberg discusses a novel CRISPR-Cas9 system using programmable, RNA-guided transposase, and highlights its implications for kilobase-scale genome engineering in cell and gene therapies.

The utility of programmable, RNA-guided CRISPR-Cas systems in genome engineering continues to evolve. Nature has afforded scientists novel and diverse gene editing functionality, from nuclease-dependent CRISPR-Cas9 to second-generation base and prime editors that do not produce double-strand breaks.

In this webinar, Dr. Sam Sternberg describes a new CRISPR-Cas9 paradigm relying on nuclease-deficient bacterial transposons that catalyze RNA-guided integration of mobile genetic elements into the genome. The discovery of a fully programmable, RNA-guided transposase lays the foundation for kilobase-scale genome engineering with broad applications for developing cell and gene therapies.

Key Topics Include:

  • The basics of first- and second-generation CRISPR-Cas technologies from a scientist at the forefront of their development
  • Mechanisms, accommodation, and cell type diversity of CRISPR-Cas programmable transposition
  • How transposase factor coordination enables highly specific, genome-wide DNA integration to target sites
  • Implications of programmable transposases that obviate the need for DNA double-strand breaks and homologous recombination

Resources

#ExpertAnswers: Sam Sternberg on Genome Engineering

Play

To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.

Presenters

Samuel H. Sternberg, ;PhD

Samuel H. Sternberg, PhD

Assistant Professor
Biochemistry and Molecular Biophysics
Columbia University

Dr. Sternberg is an assistant professor of Biochemistry and Molecular Biophysics at Columbia University in New York City, NY. Sam's lab explores the biology of CRISPR-Cas systems and transposable elements and develops these systems for genome engineering. He received his Ph.D. in Chemistry from the University of California, Berkeley, and he worked as a Scientist and Group Leader at Caribou Biosciences before joining the Columbia faculty in 2018. In addition to publishing his research in leading journals and speaking internationally, Sam remains actively involved in public outreach and ongoing discussions on the ethical issues surrounding genome editing. Together with his doctoral thesis advisor, Nobel Prize laureate Jennifer Doudna, he co-authored A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution, a popular science book about the discovery, development, and applications of CRISPR technology. Sam is the recipient of the NIH Director’s New Innovator Award, the Scaringe Award from the RNA society, the Harold Weintraub Graduate Student Award from the Fred Hutchinson Cancer Research Center, and is a Sloan Fellow, Pew Biomedical Scholar, and Schaefer Research Scholar.
Watch Webinar

Production Partner

Sanguine BioSciences

Sanguine's mission is to accelerate translational biomedical research by removing the barriers to patient participation. Through transparent communications, respectful patient support, and appropriate compensation, they keep patients engaged in the research process for a better patient experience and more impactful research biospecimens.

VIEW PROFILE
Sanguine BioSciences

Related Content